An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer.

Introduction: The EORTC-Lung Cancer Group initiated a Delphi consensus process to establish a consensual definition of resectable stage III non-small cell lung cancer (NSCLC) for the use in clinical trials, including a systematic review, survey, and review of clinical cases. Here, the survey results are presented, aimed to identify areas of controversy.

Methods: A survey was distributed among the members of six international organizations related to lung cancer.

Strengthening lung cancer screening in Europe: fostering participation, improving outcomes, and addressing health inequalities through collaborative initiatives in the SOLACE consortium.

The Strengthening the Screening of Lung Cancer in Europe (SOLACE) initiative, supported by Europe's Beating Cancer Plan, is dedicated to advancing lung cancer screening. This initiative brings together the most extensive pan-European network of respiratory and radiology experts, involving 37 partners from 15 countries. SOLACE aims to enhance equitable access to lung cancer screening by developing targeted recruitment strategies for underrepresented and high-risk populations.

Zircon geochemistry from early evolved terranes records coeval stagnant- and mobile-lid tectonic regimes.

Determining the mechanisms by which the earliest continental crust was generated and reworked is important for constraining the evolution of Earth's geodynamic, surface, and atmospheric conditions. However, the details of early plate tectonic settings often remain obscured by the intervening ~4 Ga of crustal recycling. Covariations of U, Nb, Sc, and Yb in zircon have been shown to faithfully reflect Phanerozoic whole-rock-based plate-tectonic discriminators and are therefore useful in distinguishing zircons crystallized in ridge, plume, and arc-like environments, both in the present and in deep time.

Lung cancer: an update on the multidisciplinary approach from screening to palliative care.

https://bit.ly/3XQexmp.

Stage IV nonsmall cell lung cancer treatment: oligometastatic disease and disease progression, untangling the knot.

Stage IV nonsmall cell lung cancer (NSCLC) is a heterogeneous group of patients for whom systemic therapy is decided based on tumour-biological cancer features (histology, PD-L1 expression, genomic alteration, metastatic sites) and patient characteristics (performance status, comorbidities). In most instances, some kind of systemic treatment is proposed, for which immunotherapy-based or targeted therapies are considered the standards of care in 2024. Oligometastatic NSCLC represents a specific concept during the biological spectrum from localised to metastatic disease in which only a limited number of metastatic sites can be documented.